BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ceralasertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ceralasertib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03740893-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT03740893)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: PHOENIX DDR/Anti-PD-L1 Trial: A
  Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker S
 tudy of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunoth
 erapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Neg
 ative Breast Cancer\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ceralasertib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03740893
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03579316-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT03579316)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Adavosertib With or Without Ola
 parib in Treating Patients With Recurrent Ovarian\, Primary Peritoneal\, o
 r Fallopian Tube Cancer\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ceralasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03579316
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699838-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT04699838)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Chemo-Immunotherapy Followed by
  Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive S
 tage Small Cell Lung Cancer\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ceralasertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04699838
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04704661-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ceralasertib: Phase 1 readout est. (NCT04704661)
DESCRIPTION:Ceralasertib\, phase 1.\nStudy: Testing the Combination of Two 
 Anti-cancer Drugs\, DS-8201a and AZD6738\, for The Treatment of Advanced S
 olid Tumors Expressing the HER2 Protein or Gene\, The DASH Trial\nEstimate
 d primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ceralasertib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04704661
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582538-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT05582538)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Restoring Sensitivity To Immuno
 therapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib 
 Priming Followed By Combined Durvalumab/Nab-Paclitaxel\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ceralasertib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05582538
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03780608-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT03780608)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: A Study of AZD6738 in Combinati
 on With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Che
 motherapy-Refractory Gastric Cancer\; Cohort B: Anti-PD(L)\nEstimated prim
 ary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ceralasertib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03780608
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04090567-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT04090567)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Olaparib With Cediranib or AZD6
 738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Brea
 st Cancer\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ceralasertib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04090567
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Ceralasertib (AZD6738) Alone an
 d in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
 \nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ceralasertib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03682289
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769126-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ceralasertib: Phase 2 readout est. (NCT06769126)
DESCRIPTION:Ceralasertib\, phase 2.\nStudy: Using Biomarker Tests to Select
  and Test New\, Personalized Treatments for Extensive Stage Small Cell Lun
 g Cancer\, PRISM Study\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ceralasertib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06769126
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2215@assetmemo.bio
DTSTAMP:20261121T004937Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Ceralasertib: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Ceralasertib\, phase 1/2.\nStudy: European Proof-of-Concept The
 rapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refrac
 tory Tumors\nEstimated primary completion: February 2031. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ceralasertib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/ceralasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
